Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03402256 · ClinicalTrials.gov registry record · NA
Text Messaging to Reduce Alcohol Relapse in Liver Transplant Patients
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 15
- Enrollment target
NCT03402256 is a NA study that has completed, run by Yale University. The registered enrollment target is 15 participants.
The verdict
NCT03402256, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a research study of a text-messaging intervention to reduce alcohol relapse risk in pre-transplant liver transplantation patients. This study is an 8-week, randomized controlled pilot trial to investigate the feasibility and acceptability of a text-messaging intervention for alcohol relapse prevention and stress reduction in 20 liver transplant patients with alcohol-related liver disease. The goals of the study are (1) to develop a mobile, SMS-based stress reduction and alcohol use intervention for pre- liver transplant patients with alcohol-related liver disease (ALD) and (2) to evaluate the feasibility and acceptability of the mobile intervention and its effect on rates of alcohol consumption compared to a Standard Care condition in a liver transplantation center.
Interventions
- BEHAVIORAL Text Message
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2013-03-22 |
| Est. Completion | 2014-05-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03402256
The ClinicalTrials.gov registry entry for NCT03402256 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Text Message is the first listed.
NCT03402256 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03402256 about?
NCT03402256 is a clinical study titled "Text Messaging to Reduce Alcohol Relapse in Liver Transplant Patients". This is a research study of a text-messaging intervention to reduce alcohol relapse risk in pre-transplant liver transplantation patients. This study is an 8-week, randomized controlled pilot trial to investigate the feasibility and acceptability of a text-messaging intervention for alcohol relapse ...
What is the current status of trial NCT03402256?
This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2013-03-22. Estimated completion is 2014-05-06.
What interventions are being tested in trial NCT03402256?
The interventions under investigation include: Text Message (BEHAVIORAL).
Who is sponsoring clinical trial NCT03402256?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.